Rebecca Limer

Rebecca is a senior associate in the Patents and Innovation Group. She advises clients on contentious patent matters and the commercialisation of intellectual property.

Rebecca has litigated in the High Court, Court of Appeal, and at the UK IPO. She regularly works on multi-jurisdictional cases and has particular experience advising clients in the life sciences and telecoms sectors. Prior to qualifying as a solicitor Rebecca worked in the life sciences sector, negotiating clinical trials and R&D related contracts.

CV

Since 2024 Senior Associate, Taylor Wessing

2021 - 2024 Associate, Taylor Wessing

2017 - 2021 Associate, Gowling WLG

职业发展

Since 2024 Senior Associate, Taylor Wessing

2021 - 2024 Associate, Taylor Wessing

2017 - 2021 Associate, Gowling WLG

教育

2019 IP Transactions: Law and Practice, University College London

2018 Post Graduate Diploma, Intellectual Property Law and Practice, University of Oxford

2017 Admitted as a Solicitor, England & Wales

会员资格和附属关系

IPSoc

最新新闻和观点

View Rebecca's insights

点击此处了解更多

专利与创新

The development of the UK's SEP/FRAND landscape since Unwired Planet v Huawei – part one

2026年1月30日

作者

Synapse - AI in Life Sciences

Revocation of life sciences patents in the UPC

The Unified Patent Court (UPC), active since June 2023, is seeing strong uptake in pharma and biotech. Revocation decisions show a balanced 50:50 win rate for patentees and challengers. Key legal standards on novelty, obviousness, and inventive step are emerging, though some aspects remain unclear. Strategic use of the UPC offers broad enforcement, but revocation risks are higher for single-patent portfolios. Legal uncertainties, like the Bolar exemption, still need clarification.

2025年6月17日

作者 Lydia Birch 以及 Rebecca Limer

4 / 5 观点

点击此处了解更多

Rebecca Limer

专长

执业领域和服务团队

行业

CV

职业发展

教育

会员资格和附属关系

最新新闻和观点

The development of the UK's SEP/FRAND landscape since Unwired Planet v Huawei – part one

Rebecca Limer

专长

执业领域和服务团队

行业

CV

职业发展

教育

会员资格和附属关系

最新新闻和观点

The development of the UK's SEP/FRAND landscape since Unwired Planet v Huawei – part one

Related news & insights

New Court, new approaches: How the UPC is reshaping pharmaceutical patent litigation

The EU Digital Omnibus on AI – What the political deal means

PPWR & Distribution/Franchising: Packaging compliance as a strategic necessity

Cabinet decision on the Statutory Health Insurance Contribution Stabilization Act – Financial burdens on German pharmaceutical companies

Federal Administrative Court on the Delineation between Substance-Based Medical Devices and Medicinal Products

CJEU Advocate General on Distributors’ Obligations for Medical Devices

Strengthening our product liability practice with appointment of Jamie Humphreys as partner

Complex rules, clear solutions: Your packaging compliance from a single source

Federal Court of Justice Ruling on Public Advertising for Medical Cannabis on Online Platforms

Law Against Digital Violence – New Obligations for Online Service Providers

相关人员

与我会面：